# Top 50 Biotechnology Angel Investors in United Kingdom in May 2026

## Jonathan Milner
- Type: Angel
- Location: Cambridge, Massachusetts, United States
- Relevant deals: 25
- Stages: Seed, Series A, Series B
- Focus: Biotechnology, Health Care, Medical

Having worked in the life sciences industry for over ten years as an academic researcher, Jonathan identified the market opportunity for supplying high quality antibodies to support protein interaction studies and, in 1998, founded Abcam with David Cleevely and Professor Tony Kouzarides. Jonathan is a Non-Executive Director of Horizon DiscoveryGroup plc, The Evolution Education Trust, GeoSpock Ltd and Sydicate Room Group Ltd. He is also Chairman of Axol Bioscience Ltd, PhoreMost Ltd, Repositive Limited, Definigen Limited and Cambridge Allergy Ltd. Jonathan holds an executive director position at Meltwind Limited, being a designated member of Meltwind Advisory LLP. Jonathan is an experienced entrepreneur and investor and is passionate about supporting UK life science and high-tech start-ups. He has provided considerable investment and support to over 30 companies and has assisted three AIM IPOs.

## Nadav Rosenberg
- Type: Angel
- Location: London, England, United Kingdom
- Relevant deals: 5
- Stages: Seed, Pre-Seed, Series A
- Focus: Biotechnology, Artificial Intelligence, Pharmaceutical

Nadav leads Taboola’s expansion and operations in Europe and Australia.Prior to joining Taboola, Nadav was a member of the founding team of Groupon UK & IR, taking part in building and managing Groupon’s business in the UK.Before joining Groupon, Nadav worked as a strategy consultant with McKinsey & Company in London.Nadav isbased in London and holds an MBA from INSEAD, France.

## Darrin Disley
- Type: Angel
- Location: Cambridge, Cambridgeshire, United Kingdom
- Relevant deals: 4
- Stages: Seed, Series A
- Focus: Biotechnology, Health Care, Big Data

Darrin Disley is the CEO, Director & Investor at Mogrify. He attended University of Cambridge.

## Jude Gomila
- Type: Angel
- Location: San Francisco, California, United States
- Relevant deals: 3
- Stages: Seed, Pre-Seed, Angel
- Focus: Software, Biotechnology, Information Technology

Jude Gomila is currently CEO and Founder of the startup Golden.

## Ian Hogarth
- Type: Angel
- Location: London, England, United Kingdom
- Relevant deals: 3
- Stages: Seed, Pre-Seed, Series A
- Focus: Software, E-Commerce, Health Care

Ian got a master's in machine learning at Cambridge and loves dystopian robot takeover narratives. Seven years ago, Ian realized being a choirboy came with no street cred, so he started DJing hip-hop, funk, drum & bass, and grime. Ian quit his job at Bain & Company, Singapore to start Songkick.

## Peder Nielsen
- Type: Angel
- Location: Copenhagen, Hovedstaden, Denmark
- Relevant deals: 3
- Stages: Seed
- Focus: Biotechnology, Machine Learning

Peder Nielsen - Member of the Global Advisors Network @ Global Bio Fund

## Stefano Bernardi
- Type: Angel
- Location: San Francisco, California, United States
- Relevant deals: 3
- Stages: Seed, Pre-Seed
- Focus: Software, Biotechnology, Cryptocurrency

Stefano Bernardi is the Investment Director, Climate at Fondazione ENEA Tech.

## Milad Alucozai
- Type: Angel
- Location: San Francisco, California, United States
- Relevant deals: 3
- Stages: Seed, Series A, Pre-Seed
- Focus: Biotechnology, Health Care, Medical

Dr. Milad Alucozai is an Afghan-American neuroscientist, entrepreneur, biotech executive, and global investor with nearly two decades of experience in deep tech, primarily in life sciences. He pushes the boundaries of bioengineering and computational advancements, integrating machine learning and artificial intelligence into biology and medicine.With a strong commitment to commercializing transformative technologies and fostering startup ecosystems worldwide, he is a thought leader and formal mentor for entrepreneurs through organizations like Creative Destruction Lab and the Wyss Institute at Harvard Medical School.Currently, Milad is the head of Bio and Deep Tech at BoxOne Ventures, where he spearheads the firm’s investments in early-stage companies with breakthrough scientific ideas. With nearly 80 early-stage investments, they are recognized as one of North America’s most active venture firms. He is also a Venture Partner at Entrepreneur First, a global fund that has built over 500 companies from scratch with an enterprise value of $10bn. He supports founders with strategy, scaling, business development, securing growth capital, and leadership training, often being their first investor and guiding them from startup inception to IPOs or acquisitions.He started his career in translational neuroscience and multiphysics laboratories before transitioning into founding roles at biotech startups. He is part of the founding team at Mekonos, a San Francisco-based company creating a proprietary cell-engineering platform to support the future of cell and gene therapies. He was also part of the founding team at Corstem, which specialized in machine learning and artificial intelligence software and was later acquired by Circle Cardiovascular, a platform in over 1000 hospitals and more than 40 countries. At Accenture, Milad directed teams of data scientists, designers, and engineers in developing artificial intelligence platforms for global pharmaceutical companies and hospital networks.Milad serves as a Fellow in Healthcare Engineering at the Regenstrief Center. In 2020, he served as an External Advisor to AstraZeneca. He was recognized as a National Science Foundation Scholar and Macklin Fellow at Johns Hopkins Medicine. He graduated Phi Beta Kappa with a degree in Neuroscience from Purdue University’s Honors Program. As a George J. Mitchell Scholar, he completed his master’s in Immunology and earned his doctorate from the Richard M. Fairbanks School of Public Health.

## DrPano Kroko Churchill
- Type: Angel
- Location: Seattle, Washington, United States
- Relevant deals: 3
- Stages: Angel, Series A
- Focus: Health Care, Therapeutics, Biotechnology

Pano Kroko is a legendary entrepreneur, Angel, VC and PE investor in innovation towards solving big problems. His investment emphasis is on Life Sciences, Biotech, Therapeutics, Medicine, Internet, Mobile, Communications, Clean Technology, Renewable Energy, and Environmental Finance. We have a quarterly Business Plan competition for placementin our early stage start up accelerator in Seattle Washington. We also run a program in Washington DC, and we have an Innovation Master Class Startup Weekend that runs Ten times a year in Seattle, Beijing, Silicon Valley, and in major Universities around the world.The Accelerator in Seattle & Silicon Valley is called American Angels, and the Accelerator in Washington DC is named H2O and both accept business plans and great ideas with Founders, and Executive teams right now. We would like to see StartUps in all of our areas of focus as well as anything else that is great and promising to solve Big Problems. Parallel to this we also run the CEP - Clean Energy Program incubator in Oxford UK, and the Biotech accelerator for genetics, stem cell applications, genomics, medicine, pharma and telomeres research in Cambridge UK.For our more traditional VC and PE work in the US, the American Venture Company in the US and the Investment Bank Green Capital Inc in the UK and Europe. These are our conduits of support for companies and also the Green Bonds Investments Plc. All of our organizations act as levers of positive change for impact investing, and as corporate environmental investment responsibility -- within the Finance community.In Seattle and in Silicon Valley we run the Accelerator and Early Stage Investment firm AMERICAN ANGELS where we have monthly pitches and demos for new StartUps and we also run a CEO roundtable to help promising Entrepreneurial leaders to succeed.If you or your company is interested in cooperation, presenting, funding, deal syndication or simply for submission of Executive Summaries and Business Plans for early stage angel funding and/or inclusion in the H2O Incubator/Accelerator or the Clean Energy program and the Biotech incubator, please contact us herewith: Mr Ruddy Wallace: envpar [at] gmail.com

## Ariel Poler
- Type: Angel
- Location: San Francisco, California, United States
- Relevant deals: 2
- Stages: Seed, Series A, Angel
- Focus: Software, Social Media, Internet

Ariel Poler is the Co-Founder of Reveri Health. Ariel is an Internet entrepreneur, mentor, and investor. He was the founder of IPRO, the first web analytics company, and of Topica, one of the first email communities. Ariel was a board member of Kana Software, LinkExchange, Odeo, LOLapps, and StumbleUpon. He currently serves on the boards of FreedomFinancial Network, MixTent, Strava, and Scan Inc. Ariel’s angel investments include AdMob, Flixster, Slideshare, Xobni, RockYou, and Outright, BrightRoll, Instructables, Causes, Kongregate and NexTag. Ariel holds a B.S. in Mathematics with Computer Science from MIT and an MBA from Stanford University. He is originally from Venezuela and lives in San Francisco with his wife and three children.

## Gilad Engel
- Type: Angel
- Relevant deals: 2
- Stages: Seed, Pre-Seed
- Focus: Analytics, Biotechnology, Financial Services

Gilad Engel - Partner @ Target Global

## Tim Dempsey
- Type: Angel
- Relevant deals: 2
- Stages: Seed, Series A
- Focus: Software, SaaS, Information Technology

Tim Dempsey is a Managing Partner at Epiphany Capital. He graduated from the University of Manchester.

## Edward Lando
- Type: Angel
- Location: San Francisco, California, United States
- Relevant deals: 2
- Stages: Seed, Pre-Seed
- Focus: Software, Information Technology, Health Care

Edward Lando is the Managing Partner at Pareto Holdings.

## Serge Chiaramonte
- Type: Angel
- Location: London, England, United Kingdom
- Relevant deals: 2
- Stages: Seed, Pre-Seed, Series A
- Focus: FinTech, Financial Services, E-Commerce

Serge Chiaramonte

## Paul Wicks
- Type: Angel
- Location: London, England, United Kingdom
- Relevant deals: 2
- Stages: Seed, Series A
- Focus: Real Time, Marketplace, Biotechnology

Paul is a neuropsychologist and expert in digital health, clinical trials, and patient centricity. For 13 years he led the R&D team at PatientsLikeMe, an online community for over 700,000 people living with medical conditions. Specialising in clinical research using the Internet, Paul shaped the scientific validity of the platform in generatinginsights from patient-generated health data, leading to over 110 studies including a patient-driven observational trial of lithium in ALS, numerous patient-reported outcome measures, a “dose-response” curve for the benefits of friendship between patients, and methods for patient-centered and virtual clinical trial designs.He sits on the editorial boards of the BMJ, BMC Medicine, JMIR, Digital Biomarkers and The Patient. Prior to joining PatientsLikeMe, Paul worked at the Institute of Psychiatry (King’s College London) studying cognition and neuroimaging in ALS, with a postdoc in psychological consequences of Parkinson’s disease.His work has been profiled by the BBC, NPR, CNN, BBC Radio 4, the Wall Street Journal, and the New York Times. In 2011 he was awarded MIT Technology Review’s TR35 “Humanitarian of the Year” award, recognized as a TED Fellow in 2012, and joined the inaugural FLIER Program at the Academy of Medical Sciences in 2019.

## Pratima Aiyagari
- Type: Angel
- Location: London, England, United Kingdom
- Relevant deals: 2
- Stages: Pre-Seed, Seed, Series A
- Focus: Analytics, Information Technology, Software

Pratima is a Venture Partner at Nauta Capital and is based in London. At Nauta, Pratima focuses on enterprise software and deep tech domains.Pratima has 18+ years of professional experience. She is a software developer by background and spent several years in Silicon Valley working on developing intelligent network services in the networkmanagement domain. Pratima joins Nauta from US-based cybersecurity-focused investment firm Paladin Capital. Previously, Pratima led investments and acquisitions at Cisco Corporate Development in Europe with a specific focus on ML/AI, Enterprise Collaboration and Silicon. During her investment career, Pratima led an investment or held board seats in Aimotive, Adbrain, Evrythng, Secure Code Warrior, decentriq, Dashbird, and several fund investments. She also managed investments in several companies including Behaviosec, Italtel, ip.access, and Corvil.Pratima received her MBA from INSEAD in France and an MS in computer science from the Virginia Polytechnic Institute and State University in the US. Pratima is a co-author of a US patent in the area of network device clusters and high availability.

## Jon Oringer
- Type: Angel
- Location: Miami, Florida, United States
- Relevant deals: 2
- Stages: Seed, Pre-Seed
- Focus: Software, Information Technology, E-Commerce

Jon Oringer is the founder and chairman of Shutterstock.

## Patrick Pichette
- Type: Angel
- Location: London, England, United Kingdom
- Relevant deals: 2
- Stages: Seed, Series B, Series A
- Focus: Artificial Intelligence, Machine Learning, Software

Patrick Pichette currently Board Member at LightSpeed and Twitter. He is a former Google's chief financial officer, where he started in June of 2008. He has nearly 20 years of experience in financial operations and management in the telecommunications sector, including seven years at Bell Canada, which he joined in 2001 as executive vicepresident of planning and performance management.During his time at Bell Canada, he held various executive positions, including CFO from 2002 until the end of 2003, and was instrumental in the management of the most extensive communications network in Canada and its ongoing migration to a new national IP-based infrastructure.Prior to joining Bell Canada, Patrick was a partner at McKinsey & Company, where he was a lead member of McKinsey's North American Telecom Practice. He also served as vice president and chief financial officer of Call-Net Enterprises, a Canadian telecommunications company.Patrick earned a bachelor's degree in business administration from UniversitA© du Quebec A  MontrA©al. He holds a master's degree in philosophy, politics, and economics from Oxford University, where he attended as a Rhodes Scholar. He also serves on the board of Engineers Without Borders (Canada).

## Jim Mellon
- Type: Angel
- Relevant deals: 2
- Stages: Series A, Seed
- Focus: Biotechnology, Health Care, Food and Beverage

Jim Mellon is an international investor with interests in several industries. After leaving Oxford, where he studied PPE, (Philosophy, Politics and Economics) he worked in Asia and the United States for two fund management companies, GT and Thornton, before establishing his own business in 1991. His business operations include two components, alisted fund management company called Charlemagne Capital, and an Asian mining group, Regent Pacific.In addition, Mr. Mellon is Co-Chairman of West African Minerals Corporation and Regent Pacific Group. He is on the board of a number of public quoted companies, including Brazilian Gold Corporation, Charlemagne Capital Limited, Manx Financial Group, Plethora Solutions, Polo Resources, Port Erin Biophara Investments Limited, and the Speymill plc. He is the life tenant of a trust which owns the Burnbrae Group, which has substantial assets in the biotechnology, financial services, property, mining and leisure sectors. Mr. Mellon spends most of his time working on startup ideas and investing. His book, “Wake Up!” was published in 2005; his second book "10 Investments for the Ten Years Ahead" was published in 2008. In 2012, he co-wrote "Cracking the Code" which focuses on the biotechnology sector and how to profit from it. Mr. Mellon lives in the Isle of Man, Brussels and Ibiza and is an honorary fellow of Oriel College, Oxford.

## Inaki Berenguer
- Type: Angel
- Location: New York, New York, United States
- Relevant deals: 2
- Stages: Seed, Angel, Pre-Seed
- Focus: E-Commerce, FinTech, Enterprise Software

Inaki Berenguer is the President and Co-founder at iPronics Programmable Photonics.

## Nadav Ben-Chanoch
- Type: Angel
- Location: Miami, Florida, United States
- Relevant deals: 2
- Stages: Seed, Pre-Seed
- Focus: Software, Information Technology, Health Care

Nadav Ben-Chanoch - Partner @ Pareto Holdings

## Charlie Songhurst
- Type: Angel
- Location: Greater Seattle Area, Washington, United States
- Relevant deals: 2
- Stages: Seed, Pre-Seed, Series A
- Focus: Software, Information Technology, Artificial Intelligence

Charles Songhurst is a founding partner of Katana Capital, a long-short equity hedge fund. He also runs the Songhurst Group, which holds assets in a variety of private companies.Charles ran corporate strategy for Microsoft and focused on partnering and M&A. He was involved in the Yahoo acquisition and commercial deal, and the Skypeacquisition. Before running corporate strategy, Charles was focused on the emergence of Google and the growth of the search industry.Prior, Charles was an analyst at McKinsey & Company in London. Charles received a bachelor’s degree from Oxford University in politics, philosophy, and economics.

## Ed Parkinson
- Type: Angel
- Relevant deals: 2
- Stages: Seed
- Focus: Software, Health Care, Life Science

Ed Parkinson

## Nicholas Edwards
- Type: Angel
- Location: Oxford, Oxfordshire, United Kingdom
- Relevant deals: 2
- Stages: Seed
- Focus: Medical, Health Care, Life Science

Nick serves as the Chairman of Prescient’s Board of Directors. He holds a degree in physiological sciences from The Queen’s College, University of Oxford, and completed his training in clinical medicine (BM, BCh) at Green College (now Green Templeton College), University of Oxford. Nick practiced in the areas of cardiology and general surgerybefore joining Andersen Consulting (now known as Accenture), eventually becoming the global leader of Accenture’s pharmaceutical R&D business during his 18-year tenure. In 2005, he founded Kinapse to provide consulting and outsourcing services to the pharmaceutical industry. Nick served as Kinapse’s Chairman until the company was sold to HgCapital in early 2016.

## Chris Mairs
- Type: Angel
- Location: London, England, United Kingdom
- Relevant deals: 2
- Stages: Seed, Pre-Seed, Angel
- Focus: Software, FinTech, Financial Services

Chris Mairs - Venture Partner @ Entrepreneur First

## Paul Forster
- Type: Angel
- Relevant deals: 2
- Stages: Seed, Series A, Pre-Seed
- Focus: Software, FinTech, Financial Services

Paul Forster

## Mark Evans
- Type: Angel
- Location: London, England, United Kingdom
- Relevant deals: 2
- Stages: Series A, Seed
- Focus: Software, E-Commerce, Health Care

Mark is currently a Founding Partner and LP and Investment Committee member at Kindred Capital, a European Seed-Stage Venture fund, based in London. He was a General Partner at Balderton Capital/ Benchmark Europe from 2002 through 2015, and an EIR at Benchmark Capital in 1999/2000.He spent the prior 15 years @ Goldman Sachs, where hewas a General Partner and Management Committee member. He studied Economics at both University of Oxford and Queen's University in Canada.

## Hugh Grant
- Type: Angel
- Location: Saint Louis, Missouri, United States
- Relevant deals: 2
- Stages: Seed
- Focus: Biotechnology, Machine Learning

Hugh Grant is President and Chief Executive Officer at Monsanto.

## Jan Hruska
- Type: Angel
- Relevant deals: 2
- Stages: Seed
- Focus: Medical, Health Care, Life Science

Jan Hruska

## Alex Payne
- Type: Angel
- Location: Portland, Oregon, United States
- Relevant deals: 1
- Stages: Seed, Series A
- Focus: Data Visualization, Software, Food Processing

Alex Payne the co-founder and CTO of BankSimple, an online banking disruption startup. Previously he was an Engineer at Twitter and led the API team.

## Jim Warwick
- Type: Angel
- Location: Cambridge, Cambridgeshire, United Kingdom
- Relevant deals: 1
- Stages: Seed
- Focus: Life Science, Biotechnology

Jim started work at Analysys Limited, a Cambridge-based telecommunications consultancy, heading up its IT, software and web development initiatives. Jim then joined Abcam as a Technical Director, and took over the operational management of the UK office as Managing Director in June 2004, working on both cost saving and efficiency improvementprojects. In 2009, Jim became Chief Operating Officer, with the responsibility for overseeing the operational strategy of the Group. Jim is a Director of Chesterton Community College, Chesterton Sports Centre Limited and Cambridge Nutraceuticals Limited. He has also taken up a non-executive position at Quartix Holdings Plc. Jim had over 15 years’ experience in developing and implementing IT systems and strategy before moving into a broader operational management role within Abcam.Here his skills have been particularly focused on developing a scalable operating model for Abcam which, supported by IT systems, has underpinned Abcam’s rapid growth over the past decade.

## Jon Moulton
- Type: Angel
- Relevant deals: 1
- Stages: Seed, Series A
- Focus: Financial Services, FinTech, Banking

Jon Moulton is a British venture capitalist. He is the founder and managing partner of the private equity firm Better Capital, and is the former managing partner of the private equity firm Alchemy Partners.

## David Ebsworth
- Type: Angel
- Location: Zürich, Zurich, Switzerland
- Relevant deals: 1
- Stages: Seed, Post-IPO Equity
- Focus: Pharmaceutical, Biopharma, Health Care

Dr. Ebsworth served as Chief Executive Officer of Vifor Pharma, based in Zürich, the specialty pharma division of Galenica AG Group, a pharmaceutical wholesaler and retailer, and as a member of Galenica’s Executive Committee. In 2012, Dr. Ebsworth was also named as Chief Executive Officer of Galenica and as Chairman of Galenica’s ExecutiveCommittee, positions he held until August 2014. Dr. Ebsworth received a PhD in industrial relations from the University of Surrey.

## Mark McCamish
- Type: Angel
- Location: Ventura, California, United States
- Relevant deals: 1
- Stages: Seed
- Focus: Medical, Biopharma, Biotechnology

Dr. McCamish is President and Chief Executive Officer of IconOVir Bio. Previously he was President and Chief Executive Officer of Forty Seven, Inc. He led Forty Seven, Inc. during critical phases of clinical development to help patients defeat their cancer. This included growing from a valuation of $169 million as a private company through a SeriesB offering, Initial Public Offering, two secondary fund raises and finally the acquisition of Forty Seven by Gilead for $4.9 Billion.He is an international expert in biologic and biosimilars development and manufacturing. Mark is passionate about mentoring and developing people while focusing on meeting patient needs through efficient, commercially viable efforts. He is a senior executive with extensive experience at multiple companies including Abbott, Amgen, and Novartis/Sandoz. He led pioneering efforts in filing/launching biosimilars worldwide. He has demonstrated a commercial mindset in establishing research and development strategies leading to approvals and commercial success in multiple therapeutic areas and regulatory categories including biologics, biosimilars, drugs, devices, and medical foods.He received Bachelor’s and Master’s degrees from UCSB and, after completing his PhD in Human Nutrition from Penn State and MD from UCLA, he completed Residency and Fellowship Training at the University of California, Davis. He held professorships at UC Davis and The Ohio State University

## Dave DeWalt
- Type: Angel
- Location: San Francisco, California, United States
- Relevant deals: 1
- Stages: Series A, Series C
- Focus: Cyber Security, Security, Network Security

David G. DeWalt is the Founder and Managing Director of Dave DeWalt. He joined AllegisCyber Capital as a Managing Director in 2017. Dave is a renowned cybersecurity executive, having taken cyber industry leader FireEye public (Chairman & CEO) and served as the CEO of both McAfee and Documentum.He is a member or leader of six boards ofdirectors, including ForgeRock, ForeScout, Phantom Cyber, and OPTIV, and serves as the Vice Chairman of Delta Airlines. Dave consults regularly with government, industry players, and the corporate Board of Directors on matters related to cybersecurity policy, technology, and strategy.He holds a B.S. in computer science from the University of Delaware.

## Bryan Meehan
- Type: Angel
- Location: San Francisco, California, United States
- Relevant deals: 1
- Stages: Seed, Angel, Series A
- Focus: Packaging Services, Farming, Waste Management

Bryan Meehan CEO at Blue Bottle Coffee. Previously, I co-founded Nude Skincare (acquired by LVMH) and Fresh & Wild in London (acquired by Whole Foods).I'm an advocate of socially responsible investing and co-founded Greenmont Capital, a venture firm focused on investing in people who are primarily interested in creating environmentallyfriendly products. Investments include IZZE soda line and Mary's Gone Crackers. I get very excited about great founders and have recently invested in Slack, Hampton Creek, and of course, Blue Bottle Coffee where I spend most of my time working with James Freeman and the Blue Bottle team. I'm also a very active real estate investor.I grew up in Dublin. Since, I've lived in London, Boston and San Francisco. I love music, hiking, travel, art, organic food and coffee. I'm on the Board of Trustees at De Young and Legion of Honor museums in San Francisco. I hate GMOs and campaigning hard to have food properly labelled.

## Richard Salvage
- Type: Angel
- Relevant deals: 1
- Stages: Seed
- Focus: CRM, Farming, Agriculture

Richard Salvage

## Abdulaziz Alrashed
- Type: Angel
- Relevant deals: 1
- Stages: Seed
- Focus: Analytics, Biotechnology, Information Technology

Abdulaziz Alrashed.

## Oliver Sexton
- Type: Angel
- Location: London, England, United Kingdom
- Relevant deals: 1
- Stages: Seed, Pre-Seed
- Focus: Biotechnology, Health Care, Life Science

Oliver is Head of Life Sciences at Future Planet Capital and manages investments from the UK Innovation and Science Seed Fund. He has invested in HC, ag tech, clean tech and AI businesses and sits on the board on a number of biotech companies. Prior to joining FPC, Oliver managed commercialisation of early stage HC technologies at ImperialInnovations/Touchstone and has previously managed licensing at Ark Therapeutics as well as various HC consultancy roles. He also manged a team of buy side analysts at Instinet. Oliver has an MSc from the University of Bristol and his PhD research was at the University of Nottingham.

## Sharaf Yamani
- Type: Angel
- Location: London, England, United Kingdom
- Relevant deals: 1
- Stages: Seed
- Focus: Biotechnology, Software, Life Science

Sharaf Yamani - Managing Director @ Windlesham Advisors

## Brad Wilson
- Type: Angel
- Location: Plymouth Meeting, Pennsylvania, United States
- Relevant deals: 1
- Stages: Seed
- Focus: Health Care, Biotechnology, Machine Learning

Brad Wilson Global Product Director at GlaxoSmithKline.

## Margaret Georgiadis
- Type: Angel
- Location: San Francisco, California, United States
- Relevant deals: 1
- Stages: Seed, Series A, Series B
- Focus: Health Care, Apps, Wellness

Margaret Georgiadis currently works as CEO-Partner and Co-Founder for Flagship Pioneering. She previously worked at General Catalyst as Endurance Partner In Residence. Margaret Georgiadis attended Harvard University

## Kristen Fortney
- Type: Angel
- Location: San Francisco, California, United States
- Relevant deals: 1
- Stages: Series A
- Focus: Biopharma, Health Care, Therapeutics

Kristen Fortney - CEO & Co-Founder @ BIOAGE LABS

## Chris Gibson
- Type: Angel
- Location: Salt Lake City, Utah, United States
- Relevant deals: 1
- Stages: Series A, Seed
- Focus: Biotechnology, Pharmaceutical, Health Care

Chris Gibson is the Co-Founder and CEO of Recursion (Recursion Pharmaceuticals). He previously worked at Cure HHT as a Member Board of Directors. Chris Gibson attended the University of Utah.

## Silla Scheepens
- Type: Angel
- Relevant deals: 1
- Stages: Seed
- Focus: Biotechnology, Food Processing, Food and Beverage

Silla Scheepens of Future Food Fund.

## Sami Mikati
- Type: Angel
- Relevant deals: 1
- Stages: Seed
- Focus: Biotechnology, Software, Life Science

Sami Mikati is a Director of Synthace Ltd. Investor and commercial executive with deep experience and network across energy and engineering industries in Europe, the Middle East and Africa.

## David Rowan
- Type: Angel
- Location: London, England, United Kingdom
- Relevant deals: 1
- Stages: Seed, Pre-Seed
- Focus: Software, Artificial Intelligence, Information Technology

David Rowan is editor of the UK edition of WIRED magazine, which won 2009 Launch of the David Rowan is Editor of the WIRED UK, the technology and trends magazine covering online brands, gadgets and the culture that surrounds them. David has reported on technology for The Times and Channel 4 News, the latter requiring him to illustrate the newiPod Video from the set of a porn shoot. He's also written for The Sunday Times and Telegraph Magazines, and edited the Guardian's on-line content. David has curated an exhibition of British creative talent at the Government's Cabinet Forum conference. He has also addressed the TEDs, and frequently contributes on Newsnight and the Today programme. He also writes a monthly column for GQ. David is in touch with many of the world's leading trend-setters and spotters. In presentations he looks at how the net is disrupting almost every sector, how apps change consumer behaviour and why 'social commerce' is killing traditional marketing. He reveals the 10 trends that will change your market in the next decade - and what you should be doing now to protect yourself.

## Martin Chavez
- Type: Angel
- Location: New York, New York, United States
- Relevant deals: 1
- Stages: Series A, Seed, Private Equity
- Focus: Health Care, Machine Learning, Biotechnology

Marty Chavez is executive vice president and chief financial officer of The Goldman Sachs Group, Inc. He is a member of the Management Committee, Firmwide Capital Committee, Firmwide Risk Committee and Steering Committee on Regulatory Reform. Marty is also a member of the Firmwide Hispanic/Latino Network and the Lesbian, Gay, Bisexual andTransgender Network.Marty first joined Goldman Sachs in 1993 in the J. Aron Currency and Commodities Division, where he was a senior energy strat until 1997. He returned to the firm as a managing director in Investment Banking Division Strats in 2005, becoming global co-head of Securities Division Strats and then global co-chief operating officer of the Equities Franchise. Prior to assuming his current role, Marty was chief information officer, responsible for the Technology Division and jointly responsible with divisional leadership for the firm’s global strategists. He was named partner in 2006.Prior to first joining the firm, Marty was co-founder and chief technology officer of Quorum Software Systems from 1989 to 1993. From 1997 to 2000, he was global head of energy derivatives at Credit Suisse Financial Products. In 2000, Marty co-founded Kiodex, Inc. and was chairman and chief executive officer until 2004.Marty serves on the Harvard Board of Overseers and is a Fellow of the New York Academy of Medicine.Marty earned a PhD in Medical Information Sciences from Stanford University in 1990, an SM in Computer Science from Harvard University in 1985, and an AB, magna cum laude, in Biochemical Sciences from Harvard College in 1985.

## Karl Wills
- Type: Angel
- Relevant deals: 1
- Stages: Seed
- Focus: CRM, Farming, Agriculture

Originally at MetaPack in 2000, Karl returned in November 2009 to take on the role as COO and CIO responsible for MetaPack’s Product Development, Support, Infrastructure and Carrier Integration. Karl is now responsible for handling MetaPack's legal activity and ensuring best practice is brought into all parts of the MetaPack operation toensure exceptional performance for our customers. In between the MetaPack roles, he worked for Abacus Billing as CEO before its sale to Mind CTI, successfully managing the company turnaround at Solution 1 as COO and interim CEO where he focused on improving their delivery function as well as their IT infrastructure.Prior to joining MetaPack that he has held roles such as Senior Supply Chain Director for EMI Records (based in The Netherlands), IT Director for EMI Operations and IT Director EMI France as well as a number of other UK and European IT and Logistics roles. This provides Karl with over 30 years experience in general management and the IT, logistics and warehouse industry.

## Chris Paul
- Type: Angel
- Relevant deals: 1
- Stages: Seed, Series A
- Focus: Food and Beverage, Sports, Health Care

Christopher Emmanuel Paul is an American professional basketball player for the Oklahoma City Thunder of the National Basketball Association.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co